JP2015504430A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504430A5
JP2015504430A5 JP2014542299A JP2014542299A JP2015504430A5 JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5 JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5
Authority
JP
Japan
Prior art keywords
antagonist
allele
seq
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041310 external-priority patent/WO2013077907A1/en
Publication of JP2015504430A publication Critical patent/JP2015504430A/ja
Publication of JP2015504430A5 publication Critical patent/JP2015504430A5/ja
Pending legal-status Critical Current

Links

JP2014542299A 2011-11-21 2012-06-07 Il−7アンタゴニスト及びpsa応答又は非応答対立遺伝子を用いた乾癬性関節炎(psa)を治療する方法 Pending JP2015504430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IQ3702011 2011-11-21
IQ370/2011 2011-11-21
US201261624564P 2012-04-16 2012-04-16
US61/624,564 2012-04-16
PCT/US2012/041310 WO2013077907A1 (en) 2011-11-21 2012-06-07 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles

Publications (2)

Publication Number Publication Date
JP2015504430A JP2015504430A (ja) 2015-02-12
JP2015504430A5 true JP2015504430A5 (cg-RX-API-DMAC7.html) 2015-07-23

Family

ID=48470189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542299A Pending JP2015504430A (ja) 2011-11-21 2012-06-07 Il−7アンタゴニスト及びpsa応答又は非応答対立遺伝子を用いた乾癬性関節炎(psa)を治療する方法

Country Status (12)

Country Link
US (1) US20150064193A1 (cg-RX-API-DMAC7.html)
EP (1) EP2783014A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015504430A (cg-RX-API-DMAC7.html)
KR (1) KR20140097178A (cg-RX-API-DMAC7.html)
CN (1) CN104011223A (cg-RX-API-DMAC7.html)
AR (1) AR086907A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012341081B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012101A2 (cg-RX-API-DMAC7.html)
CA (1) CA2856252A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014006158A (cg-RX-API-DMAC7.html)
RU (1) RU2014125071A (cg-RX-API-DMAC7.html)
WO (1) WO2013077907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
DK3191120T3 (da) 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
TW201639596A (zh) * 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
MA55149A (fr) * 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
MX2021014953A (es) * 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
KR20220066318A (ko) * 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
JP2024510588A (ja) * 2021-03-12 2024-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
CA3212729A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN114427001A (zh) * 2022-01-29 2022-05-03 中日友好医院(中日友好临床医学研究所) 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
AU2010276665A1 (en) * 2009-07-28 2012-02-23 Janssen Biotech, Inc. Serum markers predicting clinical response to anti-TNFalpha antibodies in patients with psoriatic arthritis
LT2625199T (lt) * 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists

Similar Documents

Publication Publication Date Title
JP2015504430A5 (cg-RX-API-DMAC7.html)
RU2014125071A (ru) Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
US12269873B2 (en) Signature of TL1A (TNFSF15) signaling pathway
JP2017513937A5 (cg-RX-API-DMAC7.html)
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
EP2848702A1 (en) Disease markers and uses thereof
EP2443257A1 (en) Method of determining response to treatment with immunomodulatory composition
JP2009039107A5 (cg-RX-API-DMAC7.html)
van Sorge et al. Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms
JP2017519498A5 (cg-RX-API-DMAC7.html)
WO2016022589A2 (en) Methods for treating multiple myeloma
CN102808030B (zh) 单核苷多态性rs3888188在检测结核病易感性中的应用
CN109837345B (zh) 检测小鼠细胞残留dna的引物及方法
Bojarojc-Nosowicz et al. Polymorphism and expression of the tumour necrosis factor-alpha (TNF-alpha) gene in non-infected cows and in cows naturally infected with the bovine leukaemia virus (BLV).
WO2011146985A1 (en) Method of determining response to treatment with immunomodulatory composition
CN109576363B (zh) 一种人abcc2基因多态性检测的引物设计方法及试剂盒
US20210148910A1 (en) Compositions and methods for treatment of atopic dermatitis and treatment selection
US20100092468A1 (en) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
JP2019520355A5 (cg-RX-API-DMAC7.html)
WO2013107005A1 (zh) 人稀有血型的多重pcr检测方法和试剂盒
KR20070004082A (ko) Fc 수용체 다형성의 확인을 위한 핵산 기반 분석
KR20220061425A (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US20180258475A1 (en) Method and device for snp genotyping
Parasannanavar et al. HLA-DRβ1* 04 typing by simple in-house PCR-SSP technique for rheumatoid arthritis patients
WO2002079503A1 (en) An allele of apolipoprotein e linked to neuropsychiatric disorders